Assessing the viability of transplanted gut microbiota by sequential tagging with D-amino acid-based metabolic probes.
Wei WangLiyuan LinYahui DuYanling SongXiaoman PengXing ChenChaoyong James YangPublished in: Nature communications (2019)
Currently, there are more than 200 fecal microbiota transplantation (FMT) clinical trials worldwide. However, our knowledge of this microbial therapy is still limited. Here we develop a strategy using sequential tagging with D-amino acid-based metabolic probes (STAMP) for assessing the viabilities of transplanted microbiotas. A fluorescent D-amino acid (FDAA) is first administered to donor mice to metabolically label the gut microbiotas in vivo. The labeled microbiotas are transplanted to recipient mice, which receive a second FDAA with a different color. The surviving transplants should incorporate both FDAAs and can be readily distinguished by presenting two colors simultaneously. Isolation of surviving bacteria and 16S rDNA sequencing identify several enriched genera, suggesting the importance of specific bacteria in FMT. In addition, using STAMP, we evaluate the effects on transplant survival of pre-treating recipients using different antibiotics. We propose STAMP as a versatile tool for deciphering the complex biology of FMT, and potentially improving its treatment efficacy.
Keyphrases
- amino acid
- living cells
- clinical trial
- small molecule
- high fat diet induced
- fluorescence imaging
- single molecule
- microbial community
- fluorescent probe
- quantum dots
- case report
- single cell
- cell therapy
- pet imaging
- stem cells
- mesenchymal stem cells
- photodynamic therapy
- replacement therapy
- label free
- positron emission tomography